Reduced left ventricular mass after treatment of obese patients with sibutramine: An echocardiographic multicentre study

Diabetes, Obesity and Metabolism

Volumn 8, Issue 6, 2006, Pages 674-681

  Wirth, Alfred ^a   Scholze, J ^b   Sharma, A M ^c   Matiba, B ^d   Boenner, G ^e  

^a Teutoburger Wald Klinik   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c MCMASTER UNIVERSITY   (Canada)

^d ABBOTT GMBH AND CO KG   (Germany)

^e Klinik Baden Privatklinik   (Germany)

Author keywords

Antiobesity agent; Blood pressure; Body composition; Clinical trial; LVM; LVM index; Weight loss

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PLACEBO; SIBUTRAMINE;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BODY FAT; BODY HEIGHT; BODY MASS; BODY SURFACE; CALORIC RESTRICTION; CLINICAL PROTOCOL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; ECHOCARDIOGRAPHY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART LEFT VENTRICLE MASS; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; OBESITY; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; SYSTOLE; WEIGHT REDUCTION; XEROSTOMIA;

EID: 33749468066     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2005.00556.x     Document Type: Article

References (27)

1. Levy D, Wilson PW, Anderson KM, Castelli WP. Stratifying the patient at risk from coronary disease: New insights from the Framingham Heart Study. Am Heart J 1990; 119: 712-717.
2. de Divitiis O, Fazio S, Petitto M, Maddalena G, Contaldo F, Mancini M. Obesity and cardiac function. Circulation 1981; 64: 477-482.
3. Messerli FH, Nunez BD, Ventura HO, Snyder DW. Overweight and sudden death. Increased ventricular ectopy in cardiopathy of obesity. Arch Intern Med 1987; 147: 1725-1728.
4. Sasson Z, Rasooly Y, Bhesania T, Rasooly I. Insulin resistance is an important determinant of left ventricular mass in the obese. Circulation 1993; 88: 1431-1436.
5. Gottdiener JS, Reda DJ, Materson BJ et al. Importance of obesity, race and age to the cardiac structural and functional effects of hypertension. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. J Am Coll Cardiol 1994; 24: 1492-1498.
6. Palmieri V, de Simone G, Arnett DK et al. Relations of various degrees of body mass index in patients with systemic hypertension to left ventricular mass, cardiac output, and peripheral resistance (The Hypertension Genetic Epidemiology Network Study). Am J Cardiol 2001; 88: 1163-1168.
7. Alpert MA, Lambert CR, Panayiotou H et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995; 76: 1194-1197.
8. Kenchaiah S, Evans JC, Levy D et al. Obesity and the risk of heart failure. N Engl J Med 2002; 347: 305-313.
9. Verdecchia P, Angeli F, Borgioni C et al. Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: A meta-analysis. AJH 2003; 16: 895-899.
10. Devereux RB, Wachtell K, Gerdts E et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 2004; 292: 2350-2356.
11. MacMahon SW, Wilcken DE, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. N Engl J Med 1986; 314: 334-339.
12. Wirth A, Kroger H. Improvement of left ventricular morphology and function in obese subjects following a diet and exercise program. Int J Obes Relat Metab Disord 1995; 19: 61-66.
13. Zannad F, Gille B, Grentzinger A et al. Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction. Am Heart J 2002; 144: 508-515.
14. Segal KR, Van Loan M, Fitzgerald PI, Hodgdon JA, Van Itallie TB. Lean body mass estimation by bioelectrical impedance analysis: A four-site cross-validation study. Am J Clin Nutr 1988; 47: 7-14.
15. Devereux RB, Lutas EM, Casale PN et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4: 12222-11230.
16. Devereux RB, Alonso DR, Lutas EM et al. Echocard-iographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. Am J Cardiol 1986; 57: 450-458.
17. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutnegger E. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999; 106: 179-184.
18. McMahon FG, Fujioka K, Singh BN et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension: A 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-2191.
19. James WPT, Astrup A, Finer N et al. for the STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. Lancet 2000; 356: 2119-2123.
20. Wirth A, Krause J. Long-term weight loss with sibutramine: A randomized controlled trial. JAMA 2001; 286: 1331-1339.
21. Hazenberg BP. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology 2000; 94: 152-158.
22. Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM. Influence of sibutramine on blood pressure: Evidence from placebo-controlled trials. Int J Obes 2005; 29: 509-516.
23. Gosse P, Roudaut R, Herrero G, Dallocchio M. Beta-blockers vs. angiotensin-converting enzyme inhibitors in hypertension: Effects on left ventricular hypertrophy. J Cardiovasc Pharmacol 1990; 16: S145-S150.
24. Kuperstein R, Sasson Z. Effects of antihypertensive therapy on glucose and insulin metabolism and on left ventricular mass: A randomized, double-blind, controlled study of 21 obese hypertensives. Circulation 2000; 102: 1802-1806.
25. Liao Y, Cooper RS, Durazo-Arvizu R, Mensah GA, Ghali JK. Prediction of mortality risk by different methods of indexation for left ventricular mass. J Am Coll Cardiol 1997; 29: 641-647.
26. Himeno E, Nishino K, Nakashima Y, Kuroiwa A, Ikeda M. Weight reduction regresses left ventricular mass regardless of blood pressure level in obese subjects. Am Heart J 1996; 131: 313-319.
27. Kuch B, Hense HW, Gneiting B et al. Body composition and prevalence of left ventricular hypertrophy. Circulation 2000; 102: 405-410.